Seng Gee Lim

机构：Agency for Science, Technology and Research, National University of Singapore, University Health System, National University Hospital, National University Health System, Institute of Molecular and Cell Biology · ORCID：0000-0003-0994-4932

发表论文 450 篇 · 总被引 26876 次 · h-index 73

代表论文

• Scientific and medical evidence informing expansion of hepatitis B treatment guidelines (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 13)
• Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment (2025 · Alimentary Pharmacology & Therapeutics · 被引 9)
• Differential HCC risk among HBV indeterminate types at baseline and by phase transition (2025 · Gut · 被引 8)
• Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL ‐B Study (2025 · Alimentary Pharmacology & Therapeutics · 被引 5)
• HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER) (2025 · Gut · 被引 4)
• Long-Term Effectiveness of Tenofovir Alafenamide Versus Entecavir in Treatment-Naive Chronic Hepatitis B: A Real-World Evidence from the Global Alliance for the Study of Hepatitis B Virus (2025 · The American Journal of Gastroenterology · 被引 2)